Display options
Cite
Sloan DJ, Davies GR, Khoo SH. Recent advances in tuberculosis: New drugs and treatment regimens. Curr Respir Med Rev. 2013;9(3):200-210doi: 10.2174/1573398x113099990017.
Sloan, D. J., Davies, G. R., & Khoo, S. H. (2013). Recent advances in tuberculosis: New drugs and treatment regimens. Current respiratory medicine reviews, 9(3), 200-210. https://doi.org/10.2174/1573398x113099990017
Sloan, Derek J, et al. "Recent advances in tuberculosis: New drugs and treatment regimens." Current respiratory medicine reviews vol. 9,3 (2013): 200-210. doi: https://doi.org/10.2174/1573398x113099990017
Sloan DJ, Davies GR, Khoo SH. Recent advances in tuberculosis: New drugs and treatment regimens. Curr Respir Med Rev. 2013 Jun 01;9(3):200-210. doi: 10.2174/1573398x113099990017. PMID: 24683386; PMCID: PMC3968807.
Copy Download .nbib Format: NLM
Share it on

Curr Respir Med Rev. 2013 Jun 01;9(3):200-210. doi: 10.2174/1573398x113099990017.

Recent advances in tuberculosis: New drugs and treatment regimens.

Current respiratory medicine reviews

Derek J Sloan, Geraint R Davies, Saye H Khoo

Affiliations

  1. Tropical and Infectious Disease Unit, Royal Liverpool University Hospital, Liverpool, L7 8XP, UK.

PMID: 24683386 PMCID: PMC3968807 DOI: 10.2174/1573398x113099990017

Abstract

The current treatment regimen against drug susceptible tuberculosis (DS-TB) was defined by the 1980s. Since then the emergence of the global HIV pandemic and the escalation of drug resistant (DR-) forms of TB have presented new challenges for therapeutic research. Priority goals include shortening DS-TB treatment, improving DR-TB treatment and making combined TB-HIV therapy easier. To help achieve these goals, a range of new drugs and treatment strategies are currently being evaluated. Phase IIb and III clinical trials are ongoing to assess combinations involving the high-dose rifamycins, the 8-methoxyquinolones, a diarylquinoline (bedaquiline) and the nitroimidazoles. Other compounds (e.g. novel oxazolidinones and ethylenediamines) are at earlier stages of clinical development. Overall, there are grounds for optimism that recent advances will contribute towards achievement of new treatment regimens in the foreseeable future. However, long-term investment, political commitment and scientific endeavour are crucial to ensure that progress is sustained and the benefits of recent advances reach those in the greatest need.

Keywords: Bedaquiline (TMC-207); Delamanid (OPC-67683); Gatifloxacin; Moxifluxacin; PA-824; Rifampicin; Rifapentine; Sterilising activity

References

  1. Clin Microbiol Rev. 2010 Jan;23(1):14-34 - PubMed
  2. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005159 - PubMed
  3. Antimicrob Agents Chemother. 2010 Aug;54(8):3402-7 - PubMed
  4. Int J Tuberc Lung Dis. 1999 Oct;3(10 Suppl 2):S231-79 - PubMed
  5. Am Rev Tuberc. 1952 Apr;65(4):357-64 - PubMed
  6. Antimicrob Agents Chemother. 2013 Mar;57(3):1428-33 - PubMed
  7. Lancet. 1978 Aug 12;2(8085):334-8 - PubMed
  8. J Antimicrob Chemother. 2005 Nov;56(5):968-74 - PubMed
  9. Antimicrob Agents Chemother. 1993 Feb;37(2):183-6 - PubMed
  10. Am J Respir Crit Care Med. 2006 Jul 1;174(1):94-101 - PubMed
  11. Lancet. 2012 Sep 15;380(9846):986-93 - PubMed
  12. Science. 2013 Jan 11;339(6116):130 - PubMed
  13. Clin Infect Dis. 2010 May 15;50 Suppl 3:S165-72 - PubMed
  14. Clin Infect Dis. 2003 Dec 1;37(11):1448-52 - PubMed
  15. Am J Respir Crit Care Med. 2004 Nov 15;170(10):1131-4 - PubMed
  16. Am Rev Respir Dis. 1981 Feb;123(2):165-70 - PubMed
  17. Future Med Chem. 2011 Sep;3(11):1427-54 - PubMed
  18. Antimicrob Agents Chemother. 2007 Mar;51(3):1011-5 - PubMed
  19. Bull World Health Organ. 1964;31:273-94 - PubMed
  20. J Biol Chem. 2008 Sep 12;283(37):25273-25280 - PubMed
  21. Scand J Infect Dis. 2001;33(6):466-9 - PubMed
  22. Antimicrob Agents Chemother. 2012 Jun;56(6):3271-6 - PubMed
  23. AIDS. 2013 Jan 28;27(3):481-4 - PubMed
  24. Antimicrob Agents Chemother. 2011 Dec;55(12):5485-92 - PubMed
  25. Chem Rev. 2005 Feb;105(2):559-92 - PubMed
  26. Am J Respir Crit Care Med. 2008 Dec 1;178(11):1180-5 - PubMed
  27. Am J Respir Crit Care Med. 2004 Feb 1;169(3):421-6 - PubMed
  28. Antimicrob Agents Chemother. 2006 Sep;50(9):3154-6 - PubMed
  29. PLoS Med. 2006 Aug;3(8):e273 - PubMed
  30. J Antimicrob Chemother. 2000 Jun;45(6):859-70 - PubMed
  31. Antimicrob Agents Chemother. 2010 Mar;54(3):1022-8 - PubMed
  32. PLoS Med. 2007 Dec;4(12):e344 - PubMed
  33. Int J Tuberc Lung Dis. 2009 Nov;13(11):1367-72 - PubMed
  34. Lancet. 1946 Jan 5;1(6384):15 - PubMed
  35. JAMA. 2013 Apr 3;309(13):1349-50 - PubMed
  36. Clin Infect Dis. 1998 Apr;26(4):874-7 - PubMed
  37. Am J Respir Crit Care Med. 2006 Feb 1;173(3):350-6 - PubMed
  38. Br Med J. 1948 Oct 30;2(4582):769-82 - PubMed
  39. Science. 2005 Jan 14;307(5707):223-7 - PubMed
  40. Am J Respir Crit Care Med. 2010 Sep 1;182(5):684-92 - PubMed
  41. Antimicrob Agents Chemother. 2008 Nov;52(11):4037-42 - PubMed
  42. Clin Chest Med. 2005 Jun;26(2):283-94, vi-vii - PubMed
  43. Antimicrob Agents Chemother. 2010 Jul;54(7):2840-6 - PubMed
  44. Antimicrob Agents Chemother. 2007 Aug;51(8):2861-6 - PubMed
  45. Int J Tuberc Lung Dis. 2011 Mar;15(3):305-16 - PubMed
  46. N Engl J Med. 2012 Jun 7;366(23):2151-60 - PubMed
  47. Lancet. 1948 Apr 17;1(6503):582-96 - PubMed
  48. Int J Tuberc Lung Dis. 2012 Apr;16(4):558-60 - PubMed
  49. N Engl J Med. 2010 Feb 25;362(8):697-706 - PubMed
  50. Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11945-50 - PubMed
  51. N Engl J Med. 2012 Oct 18;367(16):1508-18 - PubMed
  52. J Clin Microbiol. 2012 Jul;50(7):2315-20 - PubMed
  53. Br Med J. 1952 May 31;1(4769):1157-62 - PubMed
  54. Lancet. 2009 Apr 4;373(9670):1183-9 - PubMed
  55. Respirology. 2010 Jul;15(5):764-78 - PubMed
  56. Am J Respir Crit Care Med. 2006 Aug 1;174(3):331-8 - PubMed
  57. Tubercle. 1973 Jun;54(2):99-129 - PubMed
  58. Chest. 1979 Dec;76(6 Suppl):771-81 - PubMed
  59. Lancet. 2011 Jan 15;377(9761):242-50 - PubMed
  60. Int J Tuberc Lung Dis. 2012 Aug;16(8):1005-14 - PubMed
  61. Tuberculosis (Edinb). 2010 May;90(3):171-6 - PubMed
  62. Antimicrob Agents Chemother. 2012 Jun;56(6):3114-20 - PubMed
  63. Antimicrob Agents Chemother. 2008 Oct;52(10):3664-8 - PubMed
  64. Antimicrob Agents Chemother. 2003 Jul;47(7):2118-24 - PubMed
  65. Br Med J. 1952 Oct 4;2(4787):735-46 - PubMed
  66. Nature. 2000 Jun 22;405(6789):962-6 - PubMed
  67. Antimicrob Agents Chemother. 2008 Aug;52(8):2831-5 - PubMed
  68. PLoS Med. 2006 Nov;3(11):e466 - PubMed
  69. J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):455-62 - PubMed
  70. N Engl J Med. 2011 Oct 20;365(16):1492-501 - PubMed
  71. N Engl J Med. 2009 Jun 4;360(23):2397-405 - PubMed
  72. N Engl J Med. 2001 Mar 29;344(13):984-96 - PubMed
  73. Thorax. 1950 Jun;5(2):144-61 - PubMed
  74. Ann N Y Acad Sci. 2011 Dec;1241:48-70 - PubMed
  75. Br Med J. 1953 Mar 7;1(4809):521-36 - PubMed
  76. J Infect Dis. 2012 Oct 1;206(7):1030-40 - PubMed
  77. Int J Tuberc Lung Dis. 2008 Feb;12(2):128-38 - PubMed
  78. Am J Respir Crit Care Med. 2009 Aug 1;180(3):273-80 - PubMed
  79. Clin Orthop Relat Res. 2005 Aug;(437):3-6 - PubMed
  80. Lancet. 2010 May 22;375(9728):1830-43 - PubMed
  81. Antimicrob Agents Chemother. 2007 Apr;51(4):1563-5 - PubMed
  82. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):793-8 - PubMed
  83. Lancet. 2010 Jun 12;375(9731):2100-9 - PubMed
  84. Am Rev Respir Dis. 1980 Jun;121(6):939-49 - PubMed
  85. Lancet Infect Dis. 2013 Jan;13(1):27-35 - PubMed
  86. N Engl J Med. 2011 Oct 20;365(16):1471-81 - PubMed
  87. J Infect Dis. 2012 May 15;205 Suppl 2:S241-9 - PubMed

Publication Types

Grant support